Magazine Article | July 1, 2021

The Collective Benefits Of A Collaborative CFO

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

First, the differences. BioDelivery Sciences International (BDSI), where Terry Coelho is an EVP and the CFO, is not like the companies our readers typically occupy.

Most of those are profitless biopharma enterprises bravely developing new drugs or drug devices not yet approved for marketing. BDSI is a profitable, commercial company selling two drug products but no longer discovering or developing any new ones. Rather than a head of R&D, the company has a chief commercial officer; most employees are in sales, and operations are geared to the market.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader